Search
Oprelvekin
go.drugbank.com/drugs/DB00038ApprovedInvestigationalWithdrawnOprelvekin, the active ingredient in Neumega®, is recombinant Interleukin-11 (IL-11), which is produced in Escherichia coli (E. coli) by recombinant DNA technology. … With a molecular mass of approximately 19,000 daltons, the non-glycosylated protein is 177 amino acids in length in comparison to the natural IL-11, which is 178 amino acid long.
Tegafur-uracil
go.drugbank.com/drugs/DB09327ApprovedTegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4. … It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA.
Hexocyclium
go.drugbank.com/drugs/DB06787ApprovedHexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. … Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more
Methysergide
go.drugbank.com/drugs/DB00247ApprovedWithdrawnMethysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the carcinoid syndrome. … An ergot derivative that is a congener of lysergic acid diethylamide.
Synonyms: (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide, N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamideCrotalus adamanteus antivenin
go.drugbank.com/drugs/DB13893ApprovedThe majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F116]. … They are large, heavy-bodied snakes with large, broad heads with two light lines on the face [L2877].
Lumefantrine
go.drugbank.com/drugs/DB06708ApprovedInvestigationalLumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
Canertinib
go.drugbank.com/drugs/DB05424InvestigationalCanertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo.
Categories: Compounds used in a research, industrial, or household settingIcotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigationalIcotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]
Reboxetine
go.drugbank.com/drugs/DB00234ApprovedInvestigationalWithdrawnReboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD.